All lobbying filings

AVENUE SOLUTIONS

AVENUE SOLUTIONS filed a Q4 report for JAZZ PHARMACEUTICALS, INC. on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for JAZZ PHARMACEUTICALS, INC. · Specialty pharmaceuticals

All filings by AVENUE SOLUTIONS · Everything JAZZ PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing; Expiring healthcare extenders; Issues related to BIOSECURE

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.